What one share of Mirum Pharmaceuticals holds
We have three approved medicines: LIVMARLI® (maralixibat) (“Livmarli”), CHOLBAM® (cholic acid) capsules (“Cholbam”), and CTEXLI® (chenodiol) tablets (“Ctexli”).
Mirum Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $11.03 |
|---|---|
| Profit | −$15.35 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$4.08 |
| Cash and investments | $5.11 |
| Debt | $11.58 |
| Book value | −$0.16 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$4.58 | $0.02 | −$3.45 | — | $5.77 |
| 2020 | $0.00 | −$4.09 | $0.01 | −$3.54 | — | $5.78 |
| 2021 | $0.63 | −$2.77 | $0.00 | −$4.38 | — | $3.93 |
| 2022 | $2.27 | −$4.02 | $0.01 | −$3.54 | — | $3.84 |
| 2023 | $4.56 | −$4.00 | $0.00 | −$1.74 | — | $5.32 |
| 2024 | $7.09 | −$1.85 | $0.02 | $0.20 | — | $4.67 |
| 2025 | $10.39 | −$0.47 | $0.02 | $1.09 | — | $6.06 |
Common questions about Mirum Pharmaceuticals
How much does one share of Mirum Pharmaceuticals earn?
Over the last 12 months, Mirum Pharmaceuticals lost $15.35 for each share on $11.03 of sales.
Does Mirum Pharmaceuticals pay a dividend?
Mirum Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Mirum Pharmaceuticals’s book value per share?
Mirum Pharmaceuticals’s book value is negative (−$0.16 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Mirum Pharmaceuticals have?
Each share of Mirum Pharmaceuticals has $5.11 of cash and investments and $11.58 of debt, as of June 30, 2026.
What is Mirum Pharmaceuticals’s free cash flow per share?
−$4.08 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Mirum Pharmaceuticals bought back shares?
Mirum Pharmaceuticals’s share count rose about 337% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.